Available Resources

Preclinical models of childhood solid tumors (GEMMs)

GEMMs and GEMM-derived tissue samples developed at St. Jude are available for a variety of pediatric solid tumors, including neuroblastoma, retinoblastoma and osteosarcoma. Available strains are detailed on the request form.

Patient-derived orthotopic xenografts

Orthotopic xenografts have been created from a wide variety of primary pediatric solid tumors collected under the Molecular Analysis of Solid Tumors (MAST) protocol at St. Jude. Most xenografts express luciferase to enable monitoring of tumor engraftment and progression. Cryopreserved cells, fresh frozen tissue/cells, and formalin-fixed paraffin-embedded tissue blocks are available. See below for the full list of tumor types and samples. Extensive molecular and drug sensitivity data are available for many xenografts. For each of the xenograft samples, a characterization sheet will be provided when shipping samples (see example for SJNBL046_X or visual descriptions of the clonal evolution groups.) Characterization sheets can also be requested.

Neuroblastoma samples

Symbols/Abbreviations: – = not available, mo = months, N = no, Tx = treatment, Y = yes, yr = years.

Osteosarcoma samples

Symbols/Abbreviations: F = female, M = male, Tx = treatment, yr = years.

Rhabdomyosarcoma samples

Symbols/Abbreviations: ARMS = alveolar rhabdomyosarcoma, ERMS = embryonal rhabdomyosarcoma, F = female, M = male, Tx = treatment, yr = years.

Other samples

*Please note that retinoblastoma sample size is small so tissue distribution may be limited.
Symbols/Abbreviations: F = female, M = male, mth = months, Tx = treatment, yr = years.

Genomic, drug sensitivity and pharmacokinetics data

We offer data from molecular and drug sensitivity analyses of diverse pediatric solid tumors, patient-derived orthotopic xenografts and solid tumor cell lines. (Some cell lines are available; see the request form for details.)

While comprehensive raw datasets are not made available prior to publication, we are happy to accommodate many types of data requests to answer specific research questions.

Genomic sequencing and integrated epigenetic profiling have been performed on pediatric solid tumors and patient-derived orthotopic xenografts as part of the St. Jude-Washington University Pediatric Cancer Genome Project and is actively ongoing in St. Jude investigator-led labs. Available data may include:

• Whole genome sequencing (WGS)
• Whole exome sequencing (WES)
• RNA-seq
• Whole-genome bisulfite sequencing (WGBS)
• ChIP-seq

High-throughput drug screening (HTS) data are available for many pediatric solid tumor cell lines and orthotopic xenografts, including Ewing sarcoma, neuroblastoma, osteosarcoma, retinoblastoma and rhabdomyosarcoma. In addition, we offer preclinical pharmacokinetics data for a number of high-priority drugs that are being explored for activity against pediatric solid tumors. Current preclinical trial data is uploaded into OpenClinica for long-term data capture. Data from completed preclinical Phase I (tolerability), Phase II (small pilot efficacy study) and Phase III (randomized, placebo controlled) trials are available by request. For more details and descriptions of Phase I, II and III, please see Stewart et al, 2014 Cell Reports.